Suspension of trading

NeuBase Therapeutics, Inc. Share Price

O7P

US64132K2015

Biotechnology & Medical Research

Delayed Deutsche Boerse AG 07:03:16 13/05/2024 BST			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

07/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
07/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.14M 1.06M 957K 1.79M 122M 1.82M 12.72M 5.03M 63.59M 4.8M 4.69M 201M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.14M 1.06M 957K 1.79M 122M 1.82M 12.72M 5.03M 63.59M 4.8M 4.69M 201M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news: NeuBase Therapeutics, Inc.

07/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
07/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
27/06/24	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
28/05/24	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	31/10/2021

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	03/01/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-45.50%	1.39M
WUXI APPTEC CO., LTD.	+0.88%	-0.34%	+40.64%	+73.05%	65.28B
ARGENX SE	-0.15%	-0.18%	+9.60%	+77.16%	54.57B
LONZA GROUP AG	-0.30%	+1.15%	+9.26%	+100.95%	53.59B
IQVIA HOLDINGS INC.	-2.06%	+2.90%	+24.07%	+48.36%	45.03B
BEONE MEDICINES AG	-1.79%	+0.19%	+19.32%	+123.62%	42.17B
REVOLUTION MEDICINES, INC.	-1.65%	+0.96%	+237.56%	+823.66%	39.42B
CELLTRION, INC.	-2.26%	-4.14%	+15.38%	+45.53%	32.71B
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	-10.77%	+19.80%	-6.47%	24.01B
GENMAB A/S	+0.83%	+14.57%	+59.41%	+48.53%	26.5B
Average	-0.99%	+1.73%	+43.50%	+128.89%	38.33B
Weighted average by Cap.	-0.84%	+2.27%	+45.63%	+148.37%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company